Filing Flows › Lexicon Pharmaceuticals (LXRX) › Q2 2026 › vs Q2 2025
Lexicon Pharmaceuticals (LXRX) Q2 2026 vs Q2 2025 (year over year)
Lexicon Pharmaceuticals's revenue fell $28.2M (-98%) from $28.9M in Q2 2025 to $692K in Q2 2026.
Lexicon Pharmaceuticals, Q2 2026: revenue $692K (-98% year over year), net loss $31.8M, operating cash flow −$9.2M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $692K | $28.9M | −$28.2M | -98% |
| Net loss | $31.8M | −$3.3M | $35.0M | — |
| Costs & expenses | $32.5M | $28.9M | $3.6M | +12% |
| Operating costs | $27.2M | $25.1M | $2.1M | +8% |
| Interest & other, net | $5.2M | $484K | $4.8M | +982% |
| Cost of revenue | $39K | $33K | $6K | +18% |
| Research & development | $17.4M | $15.7M | $1.7M | +11% |
| SG&A | $9.8M | $9.3M | $400K | +4% |
| Operating cash sources | $31.8M | −$3.3M | $35.0M | — |
| Depreciation & amortization | $102K | $176K | −$74K | -42% |
| Share-based compensation | $3.3M | $3.2M | $141K | +4% |
| Working capital & other | $19.1M | $10.4M | $8.8M | +85% |
| Cash used in operations | $9.2M | −$17.0M | $26.2M | — |
| Net loss absorbed | $31.8M | −$3.3M | $35.0M | — |
Questions
How much did Lexicon Pharmaceuticals's revenue grow year over year in Q2 2026?
Lexicon Pharmaceuticals's revenue fell $28.2M (-98%) from $28.9M in Q2 2025 to $692K in Q2 2026.